Apomorphine subcutaneous - NeuroHealing Pharmaceuticals

Drug Profile

Apomorphine subcutaneous - NeuroHealing Pharmaceuticals

Alternative Names: NH-001

Latest Information Update: 06 Aug 2015

Price : $50

At a glance

  • Originator NeuroHealing Pharmaceuticals
  • Developer Cato Research; NeuroHealing Pharmaceuticals
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Coma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Coma
  • New Molecular Entity No
  • Available For Licensing Yes - Coma

Highest Development Phases

  • Suspended Coma

Most Recent Events

  • 26 Apr 2013 NeuroHealing Pharmaceuticals suspends enrolment in its Phase-II trial for Coma in USA (NCT00761228)
  • 23 May 2011 NeuroHealing Pharmaceuticals receives Orphan Drug status for apomorphine for Coma in European Union
  • 16 May 2011 NeuroHealing Pharmaceuticals and Cato BioVentures (Cato Research) agree to co-develop apomorphine for Coma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top